A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
- Leukemia, Myeloid, Acute
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Multiple Myeloma
- Myelodysplastic Syndromes
- Recurrence
Age: 12 years - 66+
Gender: All